Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Tharimmune, Inc. (THAR) reported insider activity on a Form 4. Director James Liddy received a stock option grant for 5,000 derivative securities on 11/03/2025 at an exercise price of $3.075 per share. The options are exercisable on 11/03/2025 and expire on 11/03/2035, covering underlying Common Stock (5,000 shares). Following this transaction, Liddy beneficially owns 55,000 derivative securities. The ownership form is reported as Direct (D).
Tharimmune (THAR) insider Vincent LoPriore filed a Form 4 reporting a grant of 90,000 stock options at an exercise price of $3.075 on 11/03/2025. The options are exercisable on 11/03/2025 and expire on 11/03/2035.
Following the transaction, LoPriore beneficially owned 190,000 derivative securities, held directly. He is listed as Executive Chairman, Director, and a 10% Owner.
Tharimmune (THAR) reported a director stock option grant. On 11/03/2025, a stock option for 5,000 shares was acquired at an exercise price of $3.075. The option is exercisable on 11/03/2025 and expires on 11/03/2035.
Following the transaction, 55,000 derivative securities were beneficially owned, held directly. The grant price of the derivative security was listed as $0.
Tharimmune (THAR) reported a director stock option grant on a Form 4. On 11/03/2025, the insider received 32,500 stock options at an exercise price of $3.075 per share, expiring on 11/03/2035. Following this grant, the insider beneficially owns 82,500 derivative securities, held direct.
Tharimmune (THAR) reported insider activity on a Form 4. A company director reported acquiring 90,000 stock options on 11/03/2025 at an exercise price of $3.075 per share. The options are first exercisable on 11/03/2025 and expire on 11/03/2035.
Following the transaction, the filing lists 190,000 derivative securities beneficially owned. The ownership is marked as Indirect (I), with a footnote referencing relationships among Gravitas Capital LP, Gravitas Capital Partners LLC, and Vincent S. LoPriore. This filing records the insider’s equity-linked position and timing terms.
Tharimmune (THAR) director Clay Kahler filed a Form 4 reporting a stock option grant. On 11/03/2025, he was awarded 17,500 stock options with a $3.075 exercise price, exercisable on 11/03/2025 and expiring on 11/03/2035.
Following the transaction, Kahler beneficially owned 67,500 derivative securities, held directly. The filing reflects routine equity compensation for a board member.
Tharimmune (THAR) CEO and director Sireesh Appajosyula reported a stock option grant for 20,000 shares at an exercise price of $3.075 on 11/03/2025.
The options are exercisable on 11/03/2025 and expire on 11/03/2035. Following the grant, the filing lists 225,962 derivative securities beneficially owned, held direct. No non‑derivative transactions were reported in Table I.
Tharimmune, Inc. announced private financing arrangements with accredited investors. The company entered into securities purchase agreements for a cash private placement of common stock at $3.075 per share and/or pre-funded warrants priced at $3.075 less $0.0001 per pre-funded warrant. A separate cryptocurrency private placement will issue pre-funded warrants at the same economic terms.
Contemporaneously, Tharimmune will issue Strategic Advisor Warrants equal to 5.00% of the aggregate number of shares sold in the offering on a fully diluted basis, with a nominal exercise price of $0.001. Purchasers agreed to lock up applicable common shares and pre-funded warrant shares until a resale registration statement is declared effective. The company also furnished an investor presentation as Exhibit 99.1.
Tharimmune entered securities purchase agreements for private placements of common stock and pre-funded warrants. Cash purchasers will buy shares at
Cash pre-funded warrants are immediately exercisable at
Tharimmune, Inc. filed a resale registration for 326,750 shares of common stock to be offered from time to time by the selling stockholder. The shares are issuable upon exercise of placement agent and series warrants tied to prior private placements in June 2024, December 2024, June 2025, and July 2025.
Tharimmune is not selling any shares in this prospectus and will not receive proceeds from the selling stockholder’s sales. The company would receive cash only if the warrants are exercised for cash. The filing states beneficial ownership limits of 4.99% or 9.99%, as applicable, on exercises. The stock trades on Nasdaq as “THAR”; the last reported sale price was $3.16 per share on October 15, 2025. As of October 15, 2025, shares outstanding were 7,608,939.
Tharimmune is a clinical-stage biotech advancing TH104 and other immunology and IO programs, and qualifies as an emerging growth company and smaller reporting company.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
